Update (June 16, 2026): Serum Bromide Monitored in Only 31.6% of Dogs vs 77.5% for Phenobarbital in US Primary Care

TL;DR. In a large US primary-care dataset, serum bromide was monitored in only about a third of dogs receiving potassium bromide, far below the rate for phenobarbital, underscoring a therapeutic-drug-monitoring gap.

What just dropped

• Retrospective multicenter study of canine idiopathic epilepsy in US primary care (https://europepmc.org/articles/PMC12926901): of 853 dogs meeting strict inclusion criteria, potassium bromide was a prescribed first-line anti-seizure drug in 11.1% of cases.
• In the same cohort, bromide serum concentration was monitored in 31.6% of dogs, while phenobarbital serum concentration was monitored in 77.5% of cases.
• A 2024 narrative review (https://europepmc.org/articles/PMC11233540) frames bromide as an old drug whose adverse effects can affect both patients and owners, and positions it largely as an alternative or add-on antiseizure medication today.

Context

Potassium bromide has a long half-life and a narrow-ish therapeutic window, so serum monitoring is central to safe use and to distinguishing breakthrough seizures from subtherapeutic concentrations or early bromism. The Pompermaier 2026 primary-care study found that prescribing patterns generally aligned with ACVIM guidance, yet therapeutic drug monitoring for bromide lagged well behind phenobarbital. The authors note this variability and the need for both updated dosing evidence and education on the value of monitoring.

The accompanying review by Gouveia and colleagues reinforces why monitoring matters: bromide has been used in veterinary epilepsy for over 30 years, its adverse effects are clinically meaningful, and its modern role is most often as an alternative or add-on agent rather than a default first choice.

What this changes in potassium bromide (KBroVet) for canine idiopathic epilepsy (https://www.thevoyage.ai/forvets/knowledge/potassium-bromide-dogs-idiopathic-epilepsy)

This dataset puts a number on a long-suspected practice gap: bromide is being prescribed but under-monitored relative to phenobarbital in everyday primary care. It strengthens the evergreen's monitoring section with real-world denominators and supports a practical takeaway — when bromide is used, serum concentration checks deserve the same priority they already receive for phenobarbital. It does not change recommended dosing, which remains a label and formulary decision.

Voyage Clinical Desk

From clinical question to SOAP draft -- cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=update-2026-06-16-kbr-bromide-tdm-underused

References

1. Pompermaier E, Morrison JA, Stabile F, De Risio L. Retrospective study on canine idiopathic epilepsy treatment in primary care practices in the United States. Front Vet Sci. 2026;13:1723038. https://europepmc.org/articles/PMC12926901
2. Gouveia D, Mandigers P, Cherubini GB. Bromide: the good, the bad, and the ugly of the oldest antiseizure medication. Front Vet Sci. 2024;11:1433191. https://europepmc.org/articles/PMC11233540

Related reads

• Potassium Bromide (KBroVet) for Canine Idiopathic Epilepsy: FDA Full Approval and Clinical Evidence
• Imepitoin Canine Idiopathic Epilepsy